在mCRPC治疗中整合PARP抑制剂:当前策略和新兴趋势
Bicky Thapa1, Navonil De Sarkar2,3,4, Subhajit Giri2,3
1Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Cancer management and research
|September 23, 2024
概括
将多 (ADP 核糖) 聚合酶抑制剂 (PARPi) 与雄激素受体信号传导抑制剂 (ARSIs) 结合起来,在转移性割抗性前列腺癌 (mCRPC) 中显示出改善的抗瘤活性. 这种组合疗法即使在没有特定DNA损伤反应 (DDR) 基因突变的患者中也是有效的.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 转移性割抗性前列腺癌 (mCRPC) 是一个严重的临床挑战,预后不佳.
- 在mCRPC中,DNA损伤反应 (DDR) 基因的变化很常见,这为治疗提供了机会.
- 聚 (ADP 核糖) 聚合酶抑制剂 (PARPi) 在DDR突变癌症中提高合成致死性.
研究的目的:
- 审查在mCRPC中将PARPi与雄激素受体信号抑制剂 (ARSIs) 结合的临床疗效和安全性.
- 分析评估这种组合治疗的第三阶段随机对照试验 (RCT) 的数据.
- 讨论患者选择策略和在mCRPC中PARPi加上ARSI治疗的新兴趋势.
主要方法:
- 在mCRPC中对III期随机对照试验 (RCT) 进行系统审查,涉及PARPi和ARSI组合.
- 对临床疗效和安全数据的分析,包括抗瘤活性和患者结局.
- 与DDR基因变异和BRCAness表型相关的治疗反应的评估.
主要成果:
- 在第一线mCRPC中,PARPi加上ARSI组合治疗与ARSI单疗相比,III期RCT显示出改善的抗瘤活性.
- 临床益处在患有DDR变异的患者中更为明显,特别是BRCA1/2突变.
- 在没有特定DDR突变的患者中也观察到抗瘤活性,这表明与BRCAness表型和雄激素受体阻断相关的更广泛的疗效.
结论:
- PARPi和ARSI的组合代表了对mCRPC的有希望的治疗策略,特别是在一线设置中.
- 基于DDR变化的患者选择可以优化治疗结果,但疗效超出了这些特定突变.
- 对患者选择和新兴趋势的进一步研究将完善PARPi加ARSI在mCRPC管理中的使用.
更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.8K
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
394
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:27Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491